Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.81 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22026149 | 0.91 | ALK (0.78) | EGFRALK | |
| SCHEMBL22025611 | 0.89 | EGFR (1.00) | EGFRALK | |
| SCHEMBL22026145 | 0.89 | EGFR (0.84) | EGFRALK | |
| SCHEMBL17410893 | 0.88 | ALK (1.00) | EGFRALK | |
| SCHEMBL22025604 | 0.88 | EGFR (1.00) | EGFRALK | |
| SCHEMBL22025620 | 0.87 | EGFR (0.86) | EGFRALK | |
| SCHEMBL24952824 | 0.86 | ALK (0.67) | EGFRALK | |
| SCHEMBL22026223 | 0.86 | EGFR (0.81) | EGFRALK | |
| SCHEMBL22025606 | 0.86 | EGFR (1.00) | EGFRALK | |
| SCHEMBL22025947 | 0.86 | EGFR (0.72) | EGFRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | EGFR, ERBB2, ERBB3 | EGFR 1/4885ALK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.